Characteristics and experiences of buprenorphine-naloxone use among polysubstance users

References

• National Institute on Drug abuse (2017). National overdose deaths from select prescription and illicit drugs: all underlying causes of death. [accessed 2017 July 5]. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates.
   Google Scholar
• Centers for Disease Control. Opioid data analysis, injury prevention & control: opioid overdose. Atlanta: CDC; 2017 [accessed 2017 Feb 23]. https://www.cdc.gov/drugoverdose/data/analysis.html.
   Google Scholar
• Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2017 [accessed 2017 Dec 9]. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
   Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80. doi:10.1038/clpt.1994.71.
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Gonzalez-Saiz F, Oñate J, Oyagűez I, Sabater E, Casado MA. Budgetary impact of buprenorphine-naloxone combination (Suboxone) in Spain. Health Econ Rev. 2012;2(3):1–9. doi:10.1186/2191-1991-2-3.
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. Buprenorphine. Rockford: SAMHSA; 2016 [accessed 2016 Dec 7]. http://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine.
   Google Scholar
• Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274:361–72.
   PubMed Web of Science ®Google Scholar
• White W. Slaying the dragon: the history of addiction treatment and recovery in America. 2nd. Bloomington: Chestnut Health System; 2014.
   Google Scholar
• QuintilesIMS Institute. Use of opioid recovery medications: recent evidence on state level Buprenorphine use and payment types. Danbury, CN: IMS Health Global Headquarters; 2016.
   Google Scholar
• Ling W, Casadonte P, Bigelow G, Kampman KM, Parkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence: a randomized control trial. Jama. 2010;304(14):1577–83. doi:10.1001/jama.2010.1427.
   Web of Science ®Google Scholar
• Anson P Suboxone: the new drug epidemic. National Pain Report. 2013 Sept 23. http://americannewsreport.com/nationalpainreport/suboxone-new-drug-epidemic-8821747.html.
   Google Scholar
• Prescriber checkup: the doctors and drugs in medicare part D: Buprenorphine-Naloxone. ProPublica, Inc; [ accessed 2016 Dec 7]. http://projects.propublica.org/checkup/drugs/8088?sort=drug_claims
   Google Scholar
• Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn’t justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff. 2011;30(8):1425–33. doi:10.1377/hlthaff.2010.0532.
   Web of Science ®Google Scholar
• Gibson A, Degenhardt L, Mattick RP, Ali R, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–68. doi:10.1111/j.1360-0443.2007.02090.x.
   PubMed Web of Science ®Google Scholar
• Chalk M, Alanis-Hirsch K, Woodworth A, Kemp J, McLellan T. FDA approved medications for the treatment of opiate dependence: literature reviews on effectiveness and cost-effectiveness. Treatment Research Institute (TRI). In: American Society of Addiction Medicine (ASAM). (2013). Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment, 115–221. http://www.asam.org/docs/advocacy/implications-for-opioid-addiction-treatment
   Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ. A randomized clinical trial of buprenorphine for prisoners: findings at 12-month post-release. Drug Alcohol Depend. 2017;172:34–42. doi:10.1016/j.drugalcdep.2016.11.037.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O’Brien SO, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441–52. doi:10.1046/j.1360-0443.2003.00335.x.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Baltimore: John Wiley & Sons, Ltd, Cochran Collaboration; 2014.
   Google Scholar
• Turner L, Kruszewski SP, Alexander GC. Trends in the use of buprenorphine by office-ebased physicians in the United States, 2003-2013. Am J Addict. 2014;20:1–6.
   Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG, Schottenfeld RS. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. New England J Med. 2006;355(4):365–74. doi:10.1056/NEJMoa055255.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Schottenfeld RS. Long‐term treatment with Buprenorphine/Naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–20. doi:10.1080/10550490701860971.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Goldsmith RJ. Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. New England J Med. 2003;349(10):949–58. doi:10.1056/NEJMoa022164.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs. 2008;22(2):99–111. doi:10.2165/00023210-200822020-00002.
   PubMed Web of Science ®Google Scholar
• Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D’Egidio P, Sakoman S. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin‐dependent individuals. Addiction. 2012;107(1):142–51. doi:10.1111/j.1360-0443.2011.03577.x.
   PubMed Web of Science ®Google Scholar
• Parran T, Adelman C, Merkin B, Pagano M, Defranco R, Ionescu R, Mace A. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60. doi:10.1016/j.drugalcdep.2009.07.013.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Byrd-Sellers J, Casarella J, Drexler K. Safety and efficacy of long-term buprenorphine maintenance treatment. Addict Disord Their Treat. 2011;10(3):123–30. doi:10.1097/ADT.0b013e318211ba0a.
   Google Scholar
• Littrell J. Expanding access to medication assisted treatment: the U.S. government’s response to the current heroin epidemic. Soc Work Ment Health. 2017;15(2):209–29.
   Web of Science ®Google Scholar
• Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302–08. doi:10.5055/jom.2007.0018.
   PubMedGoogle Scholar
• Bazazi AR, Yokel M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and non-injecting opioid users. J Addict Med. 2011;5(3):175–80. doi:10.1097/ADM.0b013e3182034e31.
   PubMed Web of Science ®Google Scholar
• Johanson C, Arfken C, di Menza S, Schuster C. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120:190–95. doi:10.1016/j.drugalcdep.2011.07.019.
   PubMed Web of Science ®Google Scholar
• Wish ED, Artigiani E, Billing A, Hauser W, Hemberg J, Shiplet M, Dupont RL. The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012;31:3–7. doi:10.1080/10550887.2011.642757.
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Lofwall M, Kim S, Chen M, Beebe K, Vocci F. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. Jama. 2016;316(3):282–90. doi:10.1001/jama.2016.9382.
   PubMed Web of Science ®Google Scholar
• Weiss R, Potter J, Provost S, Huang Z, Jacobs P, Hasson A, Lindblad R, Connery H, Prather K, Ling W. A multi-site, two-phase, prescription opioid addiction treatment study (POATS): rational, design, and methodology. Contemp Clin Trials. 2010;31:189–99. doi:10.1016/j.cct.2010.01.003.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter R, Forman R, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth. Jama. 2008;300(17):2003–11. doi:10.1001/jama.2008.574.
   PubMed Web of Science ®Google Scholar
• Denis C, Fatséas M, Beltran V, Bonnet C, Picard S, Combourieu I, Daulouède J, Auriacombe M. Validity of the self-reported drug use section of the addiction severity index and associated factors used under naturalistic conditions. Subst Use Misuse. 2012;47:356–63. doi:10.3109/10826084.2011.640732.
   PubMed Web of Science ®Google Scholar
• Mäkelä K. Studies of the reliability and validity of the addiction severity index. Addiction. 2004;99:398–410. doi:10.1111/add.2004.99.issue-4.
   PubMed Web of Science ®Google Scholar
• McLellan A, Luborsky L, Cacciola J, Griffith J, Evans F, Barr H, O’Brien C. New data from the addiction severity index. Reliability and validity in three centers. J Nervous Ment Dis. 1985;173:412–23. doi:10.1097/00005053-198507000-00005.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Measuring healthy days. Atlanta, GA: CDC; 2000 [accessed 2017 Dec 5]. https://www.cdc.gov/hrqol/pdfs/mhd.pdf
   Google Scholar
• Hennessy C, Moriarty D, Zach M, Scherr P, Brackbill R. Measuring health-related quality of life for public health surveillance. Public Health Rep. 1994;109(5):665–72.
   PubMed Web of Science ®Google Scholar
• Newschaffer C. Validation of Behavioral Risk Factor Surveillance System (BRFSS) HRQOL measures in a statewide sample. Atlanta: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1998. http://www.cdc.gov/hrqol/measurement_properties/newschaffer.htm.
   Google Scholar
• Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. doi:10.1046/j.1525-1497.2001.016009606.x.
   PubMed Web of Science ®Google Scholar
• Spitzer R, Kroenke K, Williams J, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–97. doi:10.1001/archinte.166.10.1092.
   PubMed Web of Science ®Google Scholar
• Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Prescription opioid misuse and mental health among young injection drug users. Am J Drug Alcohol Abuse. 2015;41(1):100–16. doi:10.3109/00952990.2014.940424.
   PubMed Web of Science ®Google Scholar
• Valls-Serrano C, Verdejo-Garci A, Caracuel A. Planning deficits in polysubstance dependent users: differential associations with severity of drug use and intelligence. Drug Alcohol Depend. 2016;162:72–78. doi:10.1016/j.drugalcdep.2016.02.027.
   PubMed Web of Science ®Google Scholar
• Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Prices LH, Kosten TR. Buprenorphine: duration of blockade effects of intramuscular hydromorphone. Drug Alcohol Depend. 1994;35:141–49. doi:10.1016/0376-8716(94)90121-X.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379–83. doi:10.1016/j.drugalcdep.2012.05.025.
   PubMed Web of Science ®Google Scholar
• Simeone R. Doctor shopping behavior and the diversion of opioid analgesics: 2008-2012. Albany: Simeone Associates, Inc & IMS Government Solutions; 2014.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. The dawn report: emergency department visits involving Buprenorphine. Rockville: SAMHSA; 2013.
   Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2):S39–S47. doi:10.1016/S0376-8716(03)00058-9.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coes MA, Jones JD, Nuzzo PA, Tiberg F, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017. doi:10.1001/jamapsychiatry.2017.1874.
   PubMed Web of Science ®Google Scholar
• Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange R, Contoreggie C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75(1):34–48. doi:10.1016/j.clpt.2003.09.004.
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif Z-E-H, Benth JS, Opheim A, Sharma-Hasse K, Krajci P, Kunoe N. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017. doi:10.1001/JAMAPSYCHIATRY.2017.3206.
   PubMed Web of Science ®Google Scholar
• Daubresse M, Saloner B, Pollack HA, Alexander GC. Non-buprenorphine opioid utilization among patients using buprenorphine. Addiction. 2017;112(6):1045–53. doi:10.1111/add.13762.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108:2141–49. doi:10.1111/add.12315.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci P. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. Jama. 2016;316(3):282–90. doi:10.1001/jama.2016.9382.
   PubMed Web of Science ®Google Scholar